Epizyme reports positive data from Phase I trial of tazemetostat to treat non-hodgkin lymphoma
In NHL, treatment with tazemetostat continues to demonstrate an encouraging profile with nine of 15 evaluable NHL patients achieving an objective response, including a partial response in the